Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Cardiotoxicity 3Heart Failure 2Ventricular Dysfunction 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Cardiomyopathies 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 25Paclitaxel 22Cyclophosphamide 20Docetaxel 17Taxes 14Lapatinib 13Doxorubicin 13Radiotherapy 12Bevacizumab 11Capecitabine 10Tamoxifen 9Immunohistochemistry 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Filgrastim 8Carboplatin 8Vorinostat 6Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6Chemotherapy, Adjuvant 6Biopsy 6Peripheral Blood Stem Cell Transplantation 5Everolimus 5liposomal doxorubicin 4ixabepilone 4Vinorelbine 4Neoadjuvant Therapy 4Immunoenzyme Techniques 4Gene Expression Profiling 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms, Male × Carvedilol × Clear all
NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡